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Itisnowwell acceptedthat both class I andclassII MHC-restricted T cells recog-
nize denatured or fragmented forms of protein antigens derived as a consequence
ofintracellular processing events (1-3). While there exists some evidence to suggest
that class I and class II presentation rely on distinct processing mechanisms (2, 4,
5), the extent that this difference limits the accessibility ofcertain types ofantigens
to one or another presentation pathway remains unclear. In the case of class I pre-
sentationithas been shown that, at least in vitro, exogenousnonreplicating antigens
fail to sensitize targets for CTL recognition (6). In contrast, direct introduction of
the sameproteins intothe cellcytoplasmresultsin effectiveCTLlysis(7, 8). Despite
theseinvitro studies, there is some evidenceto suggest that in vivo, exogenous anti-
gens maybe processedfor class I-restrictedT lymphocyte recognition. Forexample,
it has been shown that in MHC heterozygous Fl mice, CTL restricted to one pa-
rental MHC-encoded product can be primed against foreign minor histocompati-
bility antigens or viral antigens by introducing the antigens on cells expressing the
MHC ofthe other parent (9, 10). Consequently, these cell-associated antigens must
be taken up, processed, and then presented to CTL precursors by host cells.
In thisarticleweaddresswhetherthisobservationcanbe extended toinclude soluble
proteins. We found that exogenous protein antigens can be processed in vivo for
presentation to class I-restricted T cells provided that the antigen is introduced in
a cell-associated form.
Materials and Methods
Mice.
￿
C57BL/6 (H-2b), BALB.B (H-2b), BALB/c (H-2d), and (BALB.B x BALB/c)F,
mice were from the Scripps Clinic and Research Foundation vivarium.
Antigens.
￿
OVA (Grade VI; Sigma Chemical Co., St. Louis, MO) was used in the native
form. (3-GAL (Grade VIII; SigmaChemical Co.) wasusedinthe native formand afterboiling
in 1 M NaOH for 2 min to give an alkali digest.
Tumor Cells and Transfectants.
￿
The tumor cells used in this study were the Ia lines EL4
(C57BL/6, H-2b thymoma) and P815 (DBA/2, H-2dmastocytoma). Derivation ofthe OVA-
producing EL4 transfectant, E.G7-OVA, has been described previously (7). The S-GAL
producingtransfectant, P13.1, wasderivedby electroporation of107 P815 cells in 1 ml ofPBS
with 101~g ofPst I linearized pCH110 (Pharmacia LKB Biotechnology Inc., Piscataway, NJ)
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and 1 ug of Pvu I linearized pSV2 neo (11) followed by selection in 400 ug/ml of G418. The
C3-4 transfectant, kindly provided by Drs. H.-G. Rammensee and U. Theopold, was de-
rived from the BALB/c hybridoma igm 662 by transfecting with aplasmid encoding the/3-GAL
gene fused to the third and fourth exon of IgM heavy chain (12).
Immunization.
￿
Mice were immunized intravenously with a 200 ,1 suspension of 25 x 106
splenocytes after a protein pulse or cytoplasmic loading. For isotonic pulsing, 120 x 106
splenocytes were treated with NH4Cl/Tris to remove red blood cells and then suspended in
a 1 ml HBSS solution of protein at 10 mg/ml. After a 10 min incubation at 37 °C, the suspen-
sion was diluted with HBSS, washed twice, and the cells were irradiated (1,000 rad) before
their use for immunization. For cytoplasmic loading, 120 x 106 red blood cell depleted
splenocytes were suspended in 1 ml of a 10 mg/ml hypertonic solution of protein for 10 min
at 37°C. The hypertonic medium was made up as follows: 0.5 M sucrose, 10% w/v polyeth-
ylene glycol 1000, 10 mM Hepes, pH 7.2, in RPMI 1640 medium. The cells were rapidly
diluted in a hypotonic solution of60% HBSS and 40% water, incubated for a further 2 min
at 37°C, pelleted, and washed twice in HBSS. The cells were irradiated (1,000 rad) before
their use for immunization. Soluble proteins were injected intravenously in a volume of 200
,ul solution in HBSS.
In Vitro Stimulation ofElector Populations.
￿
Spleen cells (35 x 106 cells) from normal or im-
munized mice which had been primed 7-11 d earlier were incubated for 5 d with 3 x 106
E.G7-OVA cells (irradiated with 20,000 rad) for OVA responses or 3 x 106 C3-4 cells (ir-
radiated with 20,000 rad) for /3-GAL responses. Cultures were maintained in 10 ml of RPIO
(RPMI 1640 with 10% FCS and 50 AM 2-ME) in upright 25-cm2 flasks at 37°C in 7%
C02/air. For the experiments using in vitro depletion, spleen cells from naive C57BL/6 mice
and C57BL/6 mice primed with OVA pulsed cells were depleted of CD4 and CD8 positive
cells using guinea pig complement and the mAbs 2B6 (anti-CD4, reference 13) and 3.168
(anti-CD8, reference 14), respectively. Surviving cells were stimulated either alone or in var-
ious combinations for 5 d with irradiated E.G7-OVA cells as described above.
Cytoxiciy Assay.
￿
Target cells were used without prior treatment, or after pulsing 107 cells
for 10 min with a 1 ml solution of protein in RPMI (10 mg/ml), or after cytoplasmic loading
with a 10 mg/ml hypertonic solution as described previously (7). The cells were then labeled
with 300 uCi sodium chromate for 60 min. After washing, 104 labeled targets and serial di-
lutions of effector cells were incubated in 200 Al of RP10 for 4 h at 37°C. After a 4 h incuba-
tion at 37 °C, 100 ld of supernatant was collected and the specific lysis was determined as:
Percent specific lysis = 100 x [(release by CTL - spontaneous release)/(maximal release
- spontaneous release)] . Spontaneous release in the absence of CTL was <25 % of maximal
release by detergent in all experiments.
Results
ClassI-restricted CTL PrimingbyProteinpulsed andProtein-loadedSplenocyles.
￿
We have
derived an OVA-expressing EL4 transfectant, E.G7-OVA, that primes C57BL/6 mice
in vivo for an OVA-specific, class I-restricted CTL response. The CD8+ effectors,
specific for a determinant mapped by the peptide OVA25s-276 in association with
H-2K6, lyse EL4 in the presence of soluble OVA only if the protein is introduced
into the cell cytoplasm by osmotic lysisof pinosomes (7). To assess whether this tech-
nique could be used for in vivo immunization, we introduced soluble OVA into the
cytoplasm ofsplenocytes from C57BL/6 mice by cytoplasmic loading with a 10 mg/m1
OVA solution. These cells were injected intravenously into syngeneic mice. In addi-
tion, we also injected mice with syngeneic splenocytes that had been simply "pulsed"
with OVA, i.e., incubated for a short time in isotonic saline containing OVA. Other
mice were injected intravenously with 10-500 hg soluble OVA. Spleen cells were
taken from thesemice 7-11 d after immunization and restimulated in vitro with the
E.G7-OVA transfectant. After 5 d in culture, priming was assessed by the presenceofOVA-specific effectors capable oflysing EM-OVA. Uninjected orsaline injected
responder mice gave no OVA transfectant-specific CTL response under these con-
ditions (Fig. 1 d). Similarly, mice injected with 10-500 p,g soluble OVA showed no
evidence ofCTL priming confirming our previous results (7, 15) and shown here
for the 100 ug dose (Fig. 1 c). In contrast to this, spleen cells from responder mice
that had been injected with syngeneic OVA-loaded cells showed an excellent
transfectant-specific CTL response (Fig. 1 a). Optimal protein concentrationswere
3-10 mg/ml of OVA in hypertonic media and reproducible in vivo priming could
be achieved at concentrationsas lowas 1 mg/ml. To ourinitial surprise, an injection
ofspleen cells that had been simply incubated with OVA under isotonic conditions
also primed the CTL response (Fig. 1 b). This latter result was unexpected, since
previous in vitro experiments, usingtransfectant-specific effectors, demonstrated that
whereas cytoplasmic loading introduced soluble protein into the class I pathway of
presentation, exogenous protein addition, or pulsing, did not. Variation ofpulsing
times between 5 and 30 min did not appreciably alter the effectiveness of in vivo
priming. However, it was generallyobserved that OVA-pulsed splenocytes were some-
what less effectiveinvivoimmunogens thanwere splenocytes thathad beenput through
the cytoplasmic loading procedure (Fig. 1, a and b and data not shown).
Experimentsusing a second solubleprotein, /3-GAL from Escherichia colicombined
with adifferentmousestrain, BALB/c, paralleled those shown forOVA and C57BL/6
mice. For assaying /3-GAL-specific cytolysis, the target used was the P13.1 cell line
(P815 [DBA/2, H-2d] transfected with the pCH110 fl-GAL expression vector). Un-
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FIGURE 1.
￿
In vivo CTL priming by OVA. Spleen cells from C57BL/6 mice that had been in-
jected intravenously with (a)25 x 106 syngeneic spleen cells loaded with a 10 mg/ml hypertonic
solution of OVA, (b) 25 x 106 syngeneic spleen cells pulsed with a 10 mg/ml OVA solution in
HBSS, (c) 100,ug ofOVA, or (d)PBSwere stimulated in vitro for5 dwith E.G7-OVAcells. The
resulting effectors were then tested for lysis of 51Cr-labeled (") E.G7-OVA or (O) EL4.380
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fortunately, this cell line induced an unacceptable background CTL response in vitro
that crossreacted on the control P815 targets and was not /3-GAL specific. To cir-
cumvent this problem, we made use of a completely unrelated S-GAL-producing
transfectant of BALB/c origin, C3-4, for secondary in vitro stimulations. Fig. 2 shows
that cytoplasmic loading or pulsing with O-GAL generated BALB/c spleen cell prepa-
rations that were equally immunogenic for a P13 .1-specific CTL response. These
effectors also recognized the /3-GAL-expressing C3-4 line (data not shown) and an
alkali digest of /3-GAL (see below) showing that they are O-GAL specific. In contrast
to the sucessful priming with cell-associated a-GAL, an injection of 100 Ag soluble
/3-GAL did not prime the response (Fig. 2 c). Since neither EL4 nor P815 cells ex-
press class II MHC gene products, and the lysis shows a syngeneic restriction, these
OVA- and a-GAL-specific effectors are class I MHC restricted.
Protein-specific CTL Fail to Detect the Presentation of Exogenous Soluble Antigen.
￿
OVA-
specific CTL lines and clones derived from C57BL/6 mice primed with the E.G7-
OVA transfectant failed to lyse targets pulsed with the native protein (7). This is
also true for /3-GAL-specific, H-2d-restricted CTL derived by C3-4 priming (12,
16). It was possible that using protein-pulsed splenocytes as immunogen may have
primed for a completely different CTL effector population that could recognize ex-
ogenous antigens presented in association with class I. Figs. 3 and 4 show that this
was not the case. The E.G7-specific effectors derived from cytoplasmic loading or
protein pulsing could lyse EL4 targets only after the protein was introduced into
the cell cytoplasm by osmotic lysis of pinosomes (Fig. 3) or after the H-2K6-binding
peptide was released from OVA by CNBr treatment (data not shown).
Similar results were found for the H-2d-restricted S-GAL-specific effectors (Fig.
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FIGURE 2.
￿
In vivo CTL primingby O-GAL. Spleen cellsfrom BALB/c mice that had been in-
jected intravenously with (a) 25 x 106syngeneic spleen cells loaded with a 10 mg/mlhypertonic
solution of O-GAL, (b) 25 x 106 syngeneicspleen cells pulsed with a 10 mg/ml O-GAL solution
in HBSS, (c) 100 jigofO-GAL, or (d) PBS were stimulated in vitro for 5 dwith C3-4 cells. The
resulting effectors were then tested forlysis of 51Cr-labeled (") P13.1 or (O) P815.y
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4). Theonlysignificantdifference is therelatively weaklysisoftarget cells presenting
the cytoplasmic (3-GAL. This effect appears to be a function of the protein rather
than the effectors since CTL derived from transfectant primed mice also show a
comparablelowlevel oflysisofthese same cells (16). Recognition ofthe O-GAL alkali
EffectorlTarget Ratio
FIGURE 3.
￿
In vitrorecognition by OVA-
specific CTL requires cytosolic localiza-
tion. Effectors derived from C57BL/6mice
primed with (a)syngeneiccells aftercyto-
plasmic loading with a 10 mg/mlsolution
ofOVA or (b) syngeneiccellspulsed with
a10 mg/mlsolution ofOVAwere assayed
in a 5'Cr-release assay with (") E.G7-
OVA, (O)EL4cells alone, (*)EL4loaded
with a 10 mg/ml solution of OVA by os-
motic lysis of pinosomes, or (0) EL4
pulsed with a 10 mg/ml solution of OVA
in HBSS.
FIGURE 4. In vitro recognition by
S-GAL-specific CTLrequires cytosolic
localization. Effectors derived from
BALB/c mice primed (a) with syn-
geneic cells after cytoplasmic loading
with a 10 mg/mlsolution ofO-GALor
(b) with syngeneic cells pulsed with a
10 mg/ml solution of S-GAL were as-
sayedin a 5ICr-release assaywith (0)
P13.1, (O) P815 cellsalone, (*)P815
plus 100 pg/nil ofan alkali{9-GAL di-
gest, (/) P815 cells loaded with a 10
mg/ml solution ofO-GALby osmotic
lysis of pinosomes, or (0) P815 cells
pulsed with a 10 mg/ml solution of
fl-GAL in HBSS.382 CLASS I-RESTRICTED PROCESSING OF EXOGENOUS ANTIGEN
digest with P815 targets confirms that the effectors are specific for a degraded form
of f3-GAL (Fig. 4).
Cross-priming by Proteinpulsed Splenocytes.
￿
Previous work on in vivo priming of class
I-restricted CTL against minor histocompatibility antigens (9) showed that these
antigens, introduced on H-2 different stimulatingcells, could "cross-prime" a CTL
response in vivo. For example, B10 (H-2b) cells injected into a (BALB/c x
BALB/B)F7 (H-2d x H-2b) responder effectively primed H-2d-restricted CTL
precursors specific forB10 minor antigens. This cross-primingwas explained as the
presentation of foreign, minor histocompatibility antigens by host APCs. We de-
vised similar experiments to ascertain whether in vivo presentation of the soluble
proteins OVA and f3-GAL involves analogous APCs in the responder animal.
OVA pulsed BALB/c (H-2d), BALB.B (H-2b), and (BALB/c x BALB.B)F7
splenocytes were used to immunize Fl (BALB/c x BALB.B) mice. Spleen cells from
these and control mice were restimulated in vitro with the H-2b transfectant E.G7-
OVA for 5 d. The same H-2b target cell was used to assay the CTL effectors. As
shown in Fig. 5, thethree protein-pulsed spleen cell preparations primed OVA-specific,
H-2b-restricted CTL. Spleen cells from mice injected with control BALB/c cells
(Fig. 5 d) or BALB.B cells (data not shown) showed no evidence of priming.
In vivo primingusing0-GAL-pulsed splenocytes revealed the same cross-priming
effect (Fig. 6). In this case the significant result is that /3-GAL-pulsed H-2b cells
can be used to prime the H-2d-restricted response assayed on the P815 transfectant.
These results clearly showed that MHC class I-restricted presentation ofthe soluble
proteins introduced in association with splenocytes can involve host APCs.
Protein-pulsed Splenocytes Prime CD8+ T Cells In Vivo.
￿
It was conceivable that in
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FIGURE 5 .
￿
Cross-priming by OVA-pulsed splenocytes. (BALB.B x BALB/c)F1 mice were im-
munized with OVA pulsed (a) BALB.B, (b) BALB/c, or (c) BALB.B x BALB/c splenocytes or
(d) control BALB/c cells. Spleen cells from these mice were stimulated in vitro for 5 d with E.G7-
OVA and the resultant effectors were used in a 51Cr-release assay with ( ") E.G7-OVA and (O)
EL4.'w
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￿
Cross-priming by fl-GAL-pulsed splenocytes. (BALB.B x BALB/c)FI mice were
immunized with fl-GAL pulsed (a) BALB.B, (b) BALB/c, or (c) BALB.B x BALB/c spleen cells,
or (d) control BALB.B cells. Spleen cells from these mice were stimulated in vitro for 5 d with
C3-4 and the resultant effectors were used in a 5'Cr-release assay with ( ") P13.1 and (O) P815.
vivo injections of cell-associated protein did not lead to priming class I-restricted
CTL precursors at all, but had its effect entirely on class II-restricted helper cells.
To ascertain which of the in vivo primed cell populations was critical for the subse-
quent secondary in vitro response, we separately depleted the CD4+ and CD8' cells
from OVA-immune splenocytes. These treated populations were then stimulated in
vitro with E.G7-OVA alone, together, or in association with naive CD4+ and CD8'
populations. Table I shows that primed CD8' cells were essential for the in vitro
TABLE I
The Secondary In Vitro CTL Response to OVA Requires
In Vivo-primed CD8' T Cells
' Splenocytes from naive and OVA-pulsed splenocyte primed C57BL/6 mice
before or after antibody plus complement treatment were cultured for 5 d with
irradiated E.G7-OVA.
t 51Cr-labeled targets used in a 4-h assay at E/T ratios of 30:1/10:1 .
Source and treatment of
responder cells'
Percent specific
E.G7-OVA
lysis ofa
EL4
Naive, anti-CD8 treated (A) 4/1 4/4
Naive, anti-CD4 treated (B) 1/1 1/3
Primed, anti-CD8 treated (C) 5/2 5/3
Primed, anti-CD4 treated (D) 12/6 3/2
C plus D 39/24 6/4
C plus B 7/3 9/6
A plus D 33/21 5/3
Primed control 45/26 11/8
Naive control 14/9 16/9384
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OVA-specific response. CD8' cells from unprimed mice did not respond tothe OVA
transfectant when cultured together with primed CD4' cells. It was evident that
CD4' cells were necessary for optimal CTL stimulation in vitro, but these CD4'
cells did not require prior in vivo priming and most likely provided a source of
nonspecific lymphokine stimulation.
Discussion
In theworkpresented here we have shown how aclass I-restricted CTL response
can be primed against a soluble protein antigen. In all respects the CTL induced
byimmunization with protein mimic the activity ofeffectors generated byimmuni-
zation with cells expressing the proteins endogenously as a result ofgene transfec-
tion. The first method of in vivo priming was arrived at rationally. We had previ-
ously shown that cytoplasmic loading by the lysis of hypertonic pinocytic vesicles
was awayto get soluble protein into the MHC classIpathway ofantigen processing
(7). As expected, syngeneic spleen cells loaded with OVA or a-GAL could be used
to prime a class I-restricted CTL response (Figs. 1 a and 2 a). The second method
ofprimingthe same response was discovered by chance. In control experiments we
found that simply incubating spleen cells with OVA and O-GAL underisotonic con-
ditions ("pulsing") also gave an immunogenic preparation (Figs. 1 b and 2 b). This
was surprising, since the same treatment does not produce appropriate target cells
for class I-restricted CTL (7), nor are the pulsed cells that prime in vivo capable
of stimulating a secondary CTL response in vitro (data not shown).
Itwas conceivablethat the invivo primingeffect wasactuallydueto primed, protein-
specific CD4' helper T cells that were necessary for the in vitro activation ofpri-
mary CTL. However, the results presented in Table I ruled this out. CD4' cells
from primed mice had no effect on the in vitro activation ofCTL from naive, CD8'
populations. Furthermore, only cultures containing CD8' cells from immunized
animals showed any OVA-specific CTLactivity, consistent withthe requirementfor
in vivo priming of CD8' T cells.
Formal proofthat protein presentation for class I CTL induction could actually
occur in vivo was provided by the demonstration that antigen-pulsed splenocytes
were capable of cross-priming CTL responses in Fi mice (Figs. 5 and 6). Cross-
priminghasbeen demonstrated previously for endogenous cell-associated antigens
such as minor histocompatibility antigens (9) and SV40 T antigen (10). In these
earlier studies it was also concluded that cross-priming reflected host antigen pre-
sentation. However, while cross-sensitizationofthesecellular productscould readily
occurin vivo, no such cross-presentation wasdetected invitro(9, 10). Ananalogous
situation is found with OVA and /3-GAL responses, i.e., splenocytes pulsed with the
antigen prime the CTL response in vivo but do not reactivate CTL during 5 d in
vitro culture nor do pulsed cells serve as effective targets.
Other investigators have demonstrated that certain exogenous antigens can effec-
tively primeclass I-restricted CTL responses (17-20). However, whethertheprevi-
ously observed priming required in vivo processing was never directly assessed. At
least in the case of OVA, this has been shown to be of particular importance (15).
OVA and S-GAL were usedhereas examples ofintact andnative antigens thatclearly
required processing for effective class I presentation (Figs. 3 and 4, and referenceCARBONE AND BEVAN
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7). In this form both proteins repeatedly failed to generate CTL responses in vivo.
Consequently the two approaches that we have presented, cell pulsing and osmotic
loading, could be generally applied to a variety of solubilized antigens for effective
CTL priming.
Our explanation for the host presentation of antigens introduced on syngeneic
or allogeneic cells is that specialized cells phagocytose the injected cell or cellular
debris and the degradationproducts are fed into theclassIpathwayofpresentation.
Preliminary experiments demonstratingsuccessful CTL primingusing OVA-pulsed
and glutaraldehyde-fixed ordisrupted cells agreewith thissuggestion(datanotshown).
Pinocytosisofsolubleantigendoesnot usuallyallowaccess tothispathway. Thepostu-
lated phagocytic pathway of class I-restricted presentation would allow CTL epi-
topes expressed in peripheral cells (e.g., fibroblasts or hepatic cells) to be presented
more efficiently in the central lymphoid organs. The nature ofthe phagocytic cells
is not known. Itcouldbe a macrophage oradendriticcell. Thelatter, are not phago-
cytic in vitro afterisolation (21). However, studies using in vivo transfer ofradiola-
beled allogeneic lymphocyteshave documented themovementofradiolabel into den-
dritic celllysosomes(22). Unfortunately, thisapproach didnotunequivocably establish
that the dendritic cells became labeled due to phagocytic activity nor did it extend
the observation to syngeneic cell systems such as thosedescribedhere. Nonetheless,
the suggestion ofpotential differencesbetween invivo and in vitro phagocytic capa-
bilities for dendritic cells would fit the phenomenology of class I-restricted cross-
priming. Furtheranalysisusing otherantigens and disruptedcell preparationsshould
provide someinsightinto themechanism ofthisformofinvivo antigen presentation.
Summary
MHC class I-restricted T lymphocyte responses are usually directed to cellular
antigenic components resulting from endogenous gene expression. Exogenous, non-
replicatingantigens, such as solubleproteins, usually fail toenter theclassIpathway
ofantigen processing and presentation. Consistent with this notion, we haverecently
shown that soluble, exogenous proteins can be efficiently processed for class I pre-
sentation in vitro only ifthey are introduced directly into the target cellcytoplasm.
In this report we extend this work to the in vivo situation by introducing soluble
protein into the cytoplasm ofmouse splenocytes via the osmotic lysis ofpinosomes
and then using these cells for in vivo immunization. Our results show that cyto-
plasmic loading ofOVA and S-GAL into H-2b and H-2d splenocytes respectively,
resultedin effective invivo immunogens for class I-restricted CTL. To oursurprise,
control spleen cellpreparations simply incubated withthe exogenous, native protein
for 10 min at 37°C in isotonic medium and then washed could also induce a com-
parableclass I-restricted CTL response followingintravenous injection. Experiments
using (H-2n x H-2d)Fi mice showed that protein pulsed splenocytes from one pa-
rental strain couldeffectively"cross prime" Tcellsrestricted totheMHC oftheother
parental strain. In all cases, target cell recognition by the effector CTL generated
byimmunization with spleen cell-associated antigen required theantigentobepresent
inthe cellcytoplasm. Thus theCTLdonot recognizetarget cellsexposed to soluble,
exogenous antigen. These results, reminiscent ofanalogous experiments with cross
primingby minorhistocompatibility antigens, argue that class I-restricted processing386
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and presentation of exogenous antigen can occur in vivo following immunization
with cell-associated antigen.
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